Levodopa is often the drug of choice to mitigate the symptoms of Parkinson's disease, but getting the treatment into the bloodstream can be challenging because of the erratic muscle movement in Parkinson's patients' digestion systems. AbbVie's gel-based Duopa is designed to improve absorption of levodopa in the small intestine, and researchers at the University of Kentucky recently demonstrated long-term safety and efficacy of the delivery method.
A novel topical gel for treating migraines showed promise in a clinical trial; 77% of patients experienced pain relief.
Researchers at Seattle-based Presage Biosciences and the Fred Hutchinson Cancer Research Center have released results from a study showing further evidence their microinjection delivery device can accurately determine which cancer drugs are effective by testing multiple drugs at once inside a tumor.
3M says its new intravenous port dressing will make drug delivery easier and fight off site infections
3M announced the launch of its Tegarderm CHG intravenous port dressing, saying the device will help oncology patients receive injections comfortably and ward off infection. The new product combines a transparent port-site dressing with a chlorhexidine gluconate gel pad. 3M says the dressing enables continuous, unobstructed observation of the IV insertion site.
A team at Britain's University of Huddersfield is developing a gel that enables sustained release of medication in the digestive system, a drug delivery trick usually associated with solid formulations.
Generex's proprietary RapidMist buccal drug delivery device is finding a mark in the medical marijuana arena. The company announced its second medical marijuana outlicensing agreement, this time with Smoofi, a consultant to licensed U.S. medical and recreational marijuana operators and retail dispensaries.
The stomach and the gut are difficult places for DNA to survive and eventually pass into the bloodstream intact. Now researchers have developed nanoparticle-coated bacteria that can someday be used to create effective DNA vaccines.
Icon Bioscience has brought to light data from its late-stage extended-release cataract treatment, which demonstrated a high level of efficacy while reducing inflammation after surgery.
Fierce 15 member Mersana Therapeutics, a developer of customizable next-generation antibody-drug conjugates, announced that its lead anticancer candidate showed promise in preclinical studies.
Johnson & Johnson's diabetes care business experienced a year-over-year revenue decline of 2.2% in 2015 and fell 8.7% for the year. But J&J executives are optimistic about a turnaround, citing the recent launch of the drug-delivering Animas Vibe continuous glucose monitor and insulin pump, and longer term plans for a wearable insulin pump.
The elimination of the Medicare Sustained Growth Rate formula that threatened large Medicare reimbursement cuts to doctors on an annual basis is the most significant entitlement reform achieved by the new Congress.
In a study, Janssen Pharmaceuticals' once-a-month injectable for schizophrenia resulted in better outcomes than daily oral competitors, as measured by real-world (as opposed to strictly clinical) outcomes like arrest or psychiatric hospitalization.
FDA recalls Baxter IV solutions; Drug delivery company plunges on Wall Street following bad trial results;
J&J's Janssen Pharmaceuticals just announced a partnership involving the use of Ichor Medical Systems' TriGrid electroporation technology to deliver a DNA vaccine for hepatitis B.
Researchers at UCLA have developed a new method for the delivery of large molecules into cells. The tool has shown in early tests that it can shuttle nanoparticles, enzymes, antibodies, bacteria and other materials into cells at up to 100,000 cells per minute.
Devicemaker AngioDynamics threw its hat into the cancer drug delivery ring through its partnership with EmboMedics, the developer of investigational chemotherapy-delivering microspheres that also perform embolization.
Iowa's KemPharm, maker of abuse-resistant versions of painkillers, has set its price range for a possible IPO, seeking up to $56 million at $12 to $14 a share.
Israel's Intec Pharma is discussing a partnership involving its drug-delivering Accordion Pill with a Big Pharma player. The deal contains an option that would net Intec up $150 million, in addition to royalties on product sales.
Edge Therapeutics added $56 million to its latest financing round, bringing the total Series C haul to $72.5 million in support of its neurological candidates that overcome the blood-brain barrier through surgical delivery directly to the brain.
At the Children's Hospital of Philadelphia, researchers are looking toward biodegradable nanoparticles capable of delivering cancer drugs to neuroblastoma without harming surrounding tissue.